Biopharma & Life Sciences
Protalix BioTherapeutics Executive Compensation (FY25)
PLX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Dror Bashan | Latest say-on-pay support = June 25, 2026 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Protalix BioTherapeutics brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Data as of October 27, 2026Latest filing (8-K): June 25, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
134 figures on this page: 129 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Dror Bashan: $1,527,792 → $1,166,934 (23.6% lower)
Say-on-pay support: 68.7% → 80.9% (12.2 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Protalix BioTherapeutics' chief executive and what were they paid?
Dror Bashan, President and Chief Executive Officer, received $1,166,934 in total compensation for fiscal 2025. Compared with the $1,527,792 reported for fiscal 2024, Bashan's total was 23.6% lower.
What was Protalix BioTherapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 80.9% of votes cast for or against in favor at the meeting held June 25, 2026.
Which companies are in Protalix BioTherapeutics' peer group?
The disclosed peer group names Awards, Option and Stock.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dror Bashan President and Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Eyal Rubin Senior Vice President and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Yaron Naos Senior Vice President, Operations | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dror Bashan President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Eyal Rubin Senior Vice President and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Yaron Naos Senior Vice President, Operations | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dror Bashan President and Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Eyal Rubin Senior Vice President and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Yaron Naos Senior Vice President, Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Dror Bashan President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Eyal Rubin Senior Vice President and Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Yaron Naos Senior Vice President, Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Gilad Mamlok Senior Vice President and Chief Financial Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Dror Bashan | RSA | — | — | — | ◇ | — | — | — |
| Eyal Rubin | RSA | — | — | — | ◇ | — | — | — |
| Yaron Naos | RSA | — | — | — | ◇ | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Gilad Mamlok | Option | ◇ | — | ◇ | 7/20/2035 |
| Dror Bashan | Option | ◇ | — | ◇ | 9/3/2035 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 9/7/2032 | |
| Yaron Naos | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 9/7/2032 | |
| Option | ◇ | — | ◇ | 9/23/2034 | |
| Option | ◇ | — | ◇ | 9/3/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Eliot Richard Forster, Ph.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Gwen A. Melincoff | ◇ | — | ◇ | — | — | — | ◇ |
Pol F. Boudes, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Aharon Schwartz, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Amos Bar Shalev | ◇ | — | ◇ | — | — | — | ◇ |
Shmuel "Muli" Ben Zvi, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Christian Elze | ◇ | — | ◇ | — | — | — | ◇ |
Dror Bashan served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Awards symbol not shown
- Option OPCH
- Stock SYBT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 25, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 26, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 27, 2024 | = | ◇ | ◇ | ◇ |
| 2021 | June 30, 2022 | = | ◇ | ◇ | ◇ |
| 2019 | June 7, 2020 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Dror Bashan (President and Chief Executive Officer), FY2025 total compensation $1,166,934 (base salary $401,836) [exec_comp, SEC accession 0001104659-26-053016, filed 2026-04-30]What this page does not include
Everything above is a fact Protalix BioTherapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Protalix BioTherapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
134 figures on this page: 129 cited to the filing that reported them, 5 calculated from figures it prints.
129 cited to the filing
5 calculated from the filing
Documents cited
- 0001104659-26-077790
- 0001104659-26-053016
- 0001558370-25-008922Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001558370-24-009567Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-24-054084
- 0001558370-22-010491
- 0001104659-20-070904
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Protalix BioTherapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PLX (accessed 2026).
Short form: data: Velarion
The Protalix BioTherapeutics brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Protalix BioTherapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Protalix BioTherapeutics discloses
The companies named in PLX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}